Enanta Pharmaceuticals, Inc. — FY2013 Form 10-K
Reporting period: Fiscal year ended September 30, 2013. The filing also reports unaudited fourth-quarter results for the quarter ended September 30, 2013. All financial figures below are in U.S. dollars; amounts are in millions unless stated otherwise.
Business context
Enanta is a clinical-stage, research-and-development-focused biotechnology company developing infectious-disease medicines. Its programs target hepatitis C (HCV) and resistant bacterial infections, including MRSA. It had no approved products and no product-sales revenue; revenue came from collaborations with AbbVie and Novartis and a government contract with NIAID.
ABT-450, developed by AbbVie in combination regimens, was the most advanced program, with Phase 3 studies underway. Novartis was advancing Enanta’s HCV NS5A inhibitor EDP-239. Enanta’s independent HCV programs remained at discovery or preclinical stages, and its lead antibiotic candidate EDP-788 was in IND-enabling work.
Financial results and liquidity
| Metric | FY2013 | FY2012 |
|---|---|---|
| Revenue | $32.053 | $41.706 |
| Research and development expense | $16.841 | $15.115 |
| General and administrative expense | $6.183 | $5.302 |
| Operating income | $9.029 | $21.289 |
| Net income | $9.627 | $21.399 |
| Net income (loss) attributable to common stockholders | $(6.569) | $1.369 |
| Operating cash flow | $10.653 | $22.623 |
FY2013 revenue declined about 23% year over year, primarily because FY2012 included Novartis’s $34.4 million upfront payment. FY2013 revenue included a $15.0 million AbbVie milestone, an $11.0 million Novartis milestone, Novartis research revenue, and $4.4 million from NIAID. Common-stockholder loss despite reported net income reflected preferred-stock accretion and allocation of income to participating securities; all preferred shares converted to common stock at the March 2013 IPO.
In Q4 FY2013, revenue was $1.349 million, operating expenses were $6.050 million, other income was $0.258 million, and net loss was $4.443 million, or $0.25 per share. In Q4 FY2012, revenue was $1.858 million, operating expenses were $5.954 million, other income was $0.044 million, and net loss was $4.052 million; reported loss per share was $4.78, reflecting the pre-IPO capital structure and share count.
At September 30, 2013, cash, cash equivalents and short- and long-term marketable securities totaled $112.183 million; working capital was $100.187 million and total assets were $116.973 million. Total liabilities were $6.505 million, including a $1.620 million warrant liability. The company reported no debt outstanding. FY2013 investing cash outflow of $69.216 million largely reflected purchases of marketable securities, while financing cash inflow of $56.911 million primarily reflected IPO proceeds.
Material changes versus the prior period
- Revenue fell from $41.706 million to $32.053 million as the prior year’s Novartis upfront payment did not recur; FY2013 instead included two clinical milestones.
- R&D expense increased 11% to $16.841 million, driven mainly by higher early-stage discovery spending; G&A rose to $6.183 million, partly reflecting public-company costs and stock compensation.
- Operating income and net income declined substantially year over year. The common-stockholder result shifted from $1.369 million income to a $6.569 million loss, principally due to preferred-stock accounting and allocation.
- The March 2013 IPO generated approximately $59.9 million net of underwriting discounts and commissions; preferred stock converted to common stock. Total cash and investments rose to $112.2 million from $45.4 million.
Outlook, commentary and risks
- Management believed existing cash and investments would fund anticipated requirements for at least 24 months from September 30, 2013. It expected higher R&D spending as independent HCV and antibiotic programs advanced. Future revenue, milestones and profitability were uncertain; the company had no product revenue or royalty income.
- AbbVie reported preliminary Phase 3 results for two ABT-450 combination trials: each showed 96% SVR12 in genotype 1 patients. These were collaborator-reported preliminary results, not Enanta product sales or regulatory approvals. AbbVie targeted a potential early-2015 launch, subject to clinical, regulatory and commercial risks.
- Novartis had initiated HCV-patient studies of EDP-239. Enanta expected to advance a cyclophilin inhibitor and select a nucleotide polymerase candidate for preclinical development in 2014. It planned to initiate an EDP-788 clinical trial in Q1 2014, subject to IND-enabling progress.
- Enanta depended heavily on AbbVie and Novartis to develop and commercialize partnered candidates, with limited control over their decisions; either collaboration could be terminated under specified terms. Competition, clinical failure or delay, regulatory rejection, pricing and reimbursement pressures, manufacturing dependence, and intellectual-property challenges were material risks.
- NIAID had committed or funded approximately $23.5 million of a possible $42.7 million contract, with further funding dependent on options and government appropriations. The filing notes potential federal budget reductions and audit adjustments.
- Contractual obligations included $4.865 million of operating lease payments and $0.450 million of scheduled IP-license payments. Separately, an amended HCV-related license carries potential milestones of up to $5.0 million plus low-single-digit royalties for certain independently developed products. No material legal proceedings were reported.
Important facts for investors to verify
- Subsequent clinical and regulatory outcomes for the AbbVie ABT-450 regimen and progress of ABT-493 and Novartis’s EDP-239.
- Whether collaboration milestones, royalties and NIAID funding are achieved or continue, and how those developments affect cash runway and spending.
- Quarterly cash burn and the composition, maturities and credit quality of the $112.2 million cash-and-investment balance.
- Terms and potential impact of outstanding preferred-stock warrants, contingent IP-license obligations, and future dilution from equity awards.
- That FY2013 net income was collaboration- and contract-driven, not product-sales income, and that common-stockholder earnings differ from reported net income because of preferred-stock allocation.